We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Successful Cardiac Repair Depends on Maturity of Transplanted Stem Cells

By LabMedica International staff writers
Posted on 18 Jan 2016
A team of Japanese cells biologists has shown that the likelihood of stem cell therapy successfully repairing damaged heart muscle depends to large extent on the maturity of the stem cells at the time they are transplanted into the damaged organ.

Although transplantation of induced pluripotent stem cell (iPSC)-derived cardiomyocytes (CMs) has been reported in several animal models, the treatment effect was limited, probably due to poor optimization of the injected cells. More...


To better optimize CMs for transplantation, investigators at Kyoto University (Japan) used in vivo bioluminescence imaging to compare the engraftment efficiency of intramyocardially-injected undifferentiated-iPSCs, day four mesodermal cells, and purified iPSC-CMs 8 days, 20 days, and 30 days after initial differentiation.

They reported in the January 8, 2016, online edition of the journal Scientific Reports that the engraftment efficiency of day 20 CMs was significantly higher compared to other cell populations. Transplantation of day 20 CMs into the infarcted hearts of immunodeficient mice showed good engraftment, and echocardiography showed significant functional improvement by cell therapy. Moreover, the imaging signal at three months post injection indicated engrafted CMs proliferated in the host heart. These results suggested that day 20 CMs had very high engraftment, proliferation, and therapeutic potential in host mouse hearts.

"Cells of different maturation will be mixed and transplanted together, but heart cells at different stages could behave very differently," said first author Dr. Shunsuke Fukakoshi. "We need to test animals bigger than mice."

Related Links:

Kyoto University



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Multi-Chamber Washer-Disinfector
WD 390
New
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.